No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys.
about
Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate ModelsAutologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeysResistance to simian immunodeficiency virus low dose rectal challenge is associated with higher constitutive TRIM5α expression in PBMCMulti-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.Mucosal T-cell responses to HIV: responding at the front linesRetroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses.Stochastic theory of early viral infection: continuous versus burst production of virions.Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.Short communication: Viremic control is independent of repeated low-dose SHIVSF162p3 exposures.Genetic immunization in the lung induces potent local and systemic immune responses.The role of exposure history on HIV acquisition: insights from repeated low-dose challenge studies.Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection.Lack of detectable HIV-1-specific CD8(+) T cell responses in Zambian HIV-1-exposed seronegative partners of HIV-1-positive individualsAsymptomatic reactivation of JC virus in patients treated with natalizumab.In vivo administration of a JAK3 inhibitor to chronically siv infected rhesus macaques leads to NK cell depletion associated with transient modest increase in viral loads.HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivoNo acquisition: a new ambition for HIV vaccine development?Significant genetic heterogeneity of the SIVmac251 viral swarm derived from different sources.Mucosal simian immunodeficiency virus transmission in African green monkeys: susceptibility to infection is proportional to target cell availability at mucosal sitesPriming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cellsProtection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge.Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners.Mucosal immunity to HIV: a review of recent literature.Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challengeDelivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunityDerivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection.Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.Serial cervicovaginal exposures with replication-deficient SIVsm induce higher dendritic cell (pDC) and CD4+ T-cell infiltrates not associated with prevention but a more severe SIVmac251 infection of rhesus macaques.Tolerance and protection against infection in the genital tract.Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN).Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level
P2860
Q27318212-C5E4C763-8887-4E8B-A2EE-784427818774Q28751926-B843121D-1FB2-43AB-98B2-85FF41B51C80Q30579576-4F736DA6-CDBD-4CE3-8054-A6018B2AF8C9Q33648905-6240D5A1-BAC5-45CD-BC00-802896EB159CQ33681946-BA0E3C75-E532-4044-8245-8EF70FF2CA46Q33734859-6A96428E-0769-4A8A-B1E0-0EBFC4CB7033Q33815539-0D700A44-92F4-4DB4-BDBF-783971FE248AQ33967039-92B8F30D-F8C2-4085-8A00-FC701135AD5CQ34034659-681099B7-49F6-4BE2-8030-E1C79AF9ADB7Q34120088-12A33F15-6DC9-4328-9B0F-8819476ACC2CQ34120102-B8DDB633-8811-4766-ADB3-525E4ADA153BQ34399723-A92F5833-396A-4998-9881-FB93B8EF1DB2Q34438559-1A194169-B85F-41ED-AD72-09A72E603286Q34488291-7352D984-CAC2-44C0-AA40-F8919984B215Q34641933-BDE4D815-ED58-4CF1-9ABF-9DC321F00E81Q34763492-4E6A3915-4054-4EDF-82AF-35F75ADB56F9Q34801034-E5985DDD-DEB9-424D-AE9A-55878C340E2CQ34907640-9488755B-5042-4E3C-AB85-E44676C453B8Q35082880-935A28FB-82A9-4041-9E80-45B13B7BF18DQ35534563-7F408410-71B6-48A1-AC79-D98388956F28Q35581953-DB635AC8-3D97-41F5-B3CF-2ABA116E942CQ35868061-4B6B319D-E810-4102-957B-7A3EEAE0DD89Q36183321-3753C6D1-F4A8-4493-8B6B-566106B931C2Q36276187-04ADD8C0-E57B-43FE-9698-BBB4E271DDE5Q36539952-A733305A-FDC5-4125-A3BB-DAD6C9656F9FQ36667917-261B508E-3908-4672-8BE1-FB5BE6EC7CF5Q36827377-2EE48DA1-127A-499B-9FFE-1BED0D19BA63Q37067177-2F89B630-ADBC-4686-A7F1-BAD854B7D296Q37110714-9D681437-8546-45B5-8FC3-81CD8D42C2E9Q37123237-057CD2A1-FD57-48A9-A54C-0E5F61E70064Q37137068-3B010782-77CB-4215-B8AD-56CB494745F7Q37232824-BB7CC4AC-D311-4BE9-B855-DEB3F200B469Q37247948-155A5D50-6716-4763-845D-17325D1E3D37Q37252894-D06D2CBE-2185-4849-BA26-93CCE4587247Q37273086-154A59F2-602D-403E-BEF4-9C6465A2BEA6Q37287080-28B98362-AD64-457F-93FF-8183504F5DA9Q37619686-713F0BFF-9F00-4A6B-BE4A-E6C2FE1BA06DQ37744918-0FC1AD2A-20FF-4A72-A1CA-9647354D3262Q37854081-D0F1C221-04EC-4D96-9267-BFF469B4B7F5Q41820756-0A5EE1D0-0618-439C-B932-0FED57152C30
P2860
No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
No evidence for consistent vir ...... ed, uninfected rhesus monkeys.
@ast
No evidence for consistent vir ...... ed, uninfected rhesus monkeys.
@en
type
label
No evidence for consistent vir ...... ed, uninfected rhesus monkeys.
@ast
No evidence for consistent vir ...... ed, uninfected rhesus monkeys.
@en
prefLabel
No evidence for consistent vir ...... ed, uninfected rhesus monkeys.
@ast
No evidence for consistent vir ...... ed, uninfected rhesus monkeys.
@en
P2093
P2860
P356
P1433
P1476
No evidence for consistent vir ...... ed, uninfected rhesus monkeys.
@en
P2093
Adam P Buzby
Birgit Korioth-Schmitz
Dilani Dombagoda
Jenny G Parvani
Kevin R Carlson
Norman L Letvin
Pamela A Kozlowski
Ryon H Clarke
Srini S Rao
P2860
P304
12368-12374
P356
10.1128/JVI.00822-07
P407
P577
2007-08-08T00:00:00Z